Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Thermo Fisher Scientific and bioMérieux Renew Partnership

Published: Wednesday, October 03, 2012
Last Updated: Wednesday, October 03, 2012
Bookmark and Share
The companies have renewed their non-exclusive, long-term, royalty-bearing agreement for Procalcitonin testing.

The agreement extends a long-standing relationship between the companies for biomarker testing using Thermo Fisher’s Procalcitonin (PCT) product on bioMérieux’s VIDAS® and mini VIDAS® immunoassay platforms, and now also includes the new-generation VIDAS® products.

The PCT biomarker test is the gold standard for the early detection of sepsis in critically ill patients. In Europe, the test helps doctors make an early determination whether an infection is bacterial or viral, and provides information on the severity of a patient’s condition for appropriate treatment. In the United States, the PCT test is marketed for use on the first day of ICU admission, and, combined with other laboratory tests and clinical assessment, aids in risk assessment of critically ill patients for progression to severe sepsis and septic shock. Broader availability of PCT testing for diagnosing sepsis will lead to improved hospital management and patient care.

“The continuation of our close collaboration with bioMérieux and the installed base of VIDAS® equipment worldwide significantly strengthen our ability to make PCT testing available to a broader patient population,” said Marc Tremblay, president of Thermo Fisher Scientific’s Clinical Diagnostics business. “Earlier detection of sepsis improves patient care and reduces treatment costs. It will also provide a much needed boost to hospitals struggling to maintain service levels and remain competitive.”

“As the world leader in microbiology, bioMérieux has a long-standing commitment to the prevention and management of sepsis through dedicated diagnostic solutions and educational initiatives,” added Jean-Luc Belingard, chairman and CEO of bioMérieux. “The Thermo Scientific B•R•A•H•M•S PCT biomarker has represented a breakthrough in the field of sepsis and we are pleased to continue to work with them to make their high medical value biomarker available to a greater number of clinicians on our VIDAS® system.”

VIDAS® B•R•A•H•M•S PCT is available worldwide, and bioMérieux received 510(k) clearance from the U.S. Food and Drug Administration for the assay in 2007. The VIDAS® platform has the largest installed base worldwide in immunoassay laboratories and is well-suited to emergency situations.

Severe sepsis strikes more than 750,000 Americans each year, and between 28 to 50 percent of patients affected die within the first month of diagnosis. Hospital costs to treat severe sepsis in the U.S. are estimated at $16 billion dollars annually1. Much of this cost is attributed to misdiagnosis or delayed diagnosis, making rapid, more reliable detection a national, if not global, imperative. Research published in Critical Care Medicine showed that each hour of delay in therapy can decrease chances of patient survival by 7.6 percent.



Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Thermo Scientific Opens Molecular Biology Center of Excellence in Lithuania
New facility expands R&D and manufacturing capabilities in eastern Europe for molecular, protein and cellular biology products.
Friday, September 21, 2012
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Faecal Bacteria Linked to Body Fat
Researchers at King’s College London have found a new link between the diversity of bacteria in human poo – known as the human faecal microbiome - and levels of abdominal body fat.
‘Cellbots’ Chase Down Cancer, Deliver Drugs Directly to Tumors
Programmable T cells shown to be versatile, precise, and powerful in lab studies.
Anti-Inflammatory Drugs Could Strengthen Airway Immunity
Mold toxins can weaken the airways' clearing mechanisms and immunity, but PKC inhibitors showed promise as a treatment.
Antibodies Paving the Way to HIV Vaccine
Researchers uncover factors responsible for the formation of broadly neutralizing HIV antibodies in humans.
Vaccine Against Common Cold Achievable
Researchers suggest that a vaccine against rhinoviruses is possible using variant virus vaccines.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Iron Nanoparticles Make Immune Cells Attack Cancer
Researchers accidentally discover that nanoparticles invented for anemia treatment can trigger the immune system’s ability to destroy tumor cells.
Uncovering Cancer’s ‘Invisibility Cloak’
Researchers discover cancer cell mechanism to become invisible to the body's immune system.
Culex Mosquitoes Do Not Transmit Zika
A study of the Culex species mosquito appears to show that the species does not transmit Zika virus.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!